![Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET](https://images.squarespace-cdn.com/content/v1/60b687d7c75a235d721c70d5/8c900f9c-6d15-45da-8393-2b43144a123d/Princess+Maxima.png)
Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET
Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET
Dr. Max M. van Noesel, MD. PhD, MSc; – Princess Máxima Center, Utrecht, The Netherlands
Comprehensive molecular profiling of pediatric adrenal tumors
Comprehensive molecular profiling of pediatric adrenal tumors
Dr. Ronald de Krijger – Princess Máxima Center, Utrecht, The Netherlands
Pulmonary complications in children with solid tumors
Pulmonary complications in children with solid tumors
Dr. S.M.P.J. Prevaes; Dr. M. van Grotel – Princess Máxima Center, Utrecht, The Netherlands
Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma
Androgen activity in the normal male embryonic hindbrain drives lethal PFA ependymoma
Dr. Jiao Zhang, Ph.D. – Baylor College of Medicine, Houston TX
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Dr. Jason Sheltzer, Ph.D. – Yale University, New Haven, CT
Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma
Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma
Dr. Rosa Nguyen, M.D., Ph.D. – National Cancer Institute, NIH NCI Pediatric Oncology, Bethesda, MD
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Dr. Julia Maxson, Ph.D. – Oregon Health & Science University – OHSU, Portland, OR
Therapeutic downregulation of core circuitry genes in mutant MYOD1 rhabdomyosarcoma
Therapeutic downregulation of core circuitry genes in mutant MYOD1 rhabdomyosarcoma
Dr. Berkley Gryder, Ph.D. – Case Western Reserve University School of Medicine, Cleveland, OH
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO
Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy
Targeted Nanoparticles for Genetic Engineering of Human Natural Killer Cells for Neuroblastoma Therapy
Dr. Ketan Ghaghada, Ph.D. – Baylor College of Medicine, Houston TX
HBEGF as a novel therapeutic target for Diffuse Midline Glioma
HBEGF as a novel therapeutic target for Diffuse Midline Glioma
Dr. Oren Becher, M.D. – Icahn School of Medicine at Mount Sinai, New York, NY
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
Therapeutic targeting of CDK12/13 and PARP in H3G34RN mutant pediatric glioma
Dr. Jamie Anastas, Ph.D. – Baylor College of Medicine, Houston, TX
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
Dr. lannis Aifantis, Ph.D. – New York University Grossman School of Medicine, New York, NY
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
Dr. Norihiro Watanabe, Ph.D. – Baylor College of Medicine
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Dr. Kristopher Sarosiek, Ph.D. – President and Fellows of Harvard College, Harvard T. H. Chan School of Public Health, Boston, MA
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
Dr. Hiroto Inaba, M.D. – St. Jude Children's Research Hospital, Inc., Memphis, TN
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Developing Human Cerebellar Organoid Models of Group 4 Medulloblastoma to Identify the Cell of Origin and Mechanisms that Support Oncogenesis
Dr. Yanxin Pei, M.D. – Children's Research Institute (CNMC), Washington, D.C.